Non-alcoholic Steatohepatitis Clinical Trials Market size is expected to reach USD 4.2 billion by 2030
Non-alcoholic Steatohepatitis Clinical Trials Industry Overview The global non-alcoholic steatohepatitis clinical trials market size was valued at USD 2.42 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 6.5% from 2022 to 2030 The growth can be attributed to factors, such as increased drug R&D, rising prevalence of obesity & diabetes mainly due to sedentary lifestyles, and unmet medical needs. The COVID-19 pandemic and the FDA’s request for further post-interim safety and effectiveness data have slowed the final approval of phase III trial evaluating obeticholic acid for non-alcoholic Steatohepatitis (NASH), drug development. The COVID-19 pandemic in 2020 drew attention to the various vulnerabilities of those living with conditions, such as diabetes and obesity. The largest risk of COVID-19 is associated with NASH. The pandemic resulted in halts in the trials due to limited patient involvement in the clinical trials ...